Mometasone furoate: an effective anti‐inflammatory with a well‐defined safety and tolerability profile in the treatment of asthma

  title={Mometasone furoate: an effective anti‐inflammatory with a well‐defined safety and tolerability profile in the treatment of asthma},
  author={Jean Bousquet},
  journal={International Journal of Clinical Practice},
  • J. Bousquet
  • Published 1 May 2009
  • Medicine
  • International Journal of Clinical Practice
Inhaled corticosteroids (ICS) are recommended as a controller medication in the most recent Global Initiative for Asthma and the National Heart, Lung and Blood Institute guidelines. Mometasone furoate (MF) is an effective, well‐tolerated inhaled steroid and is indicated for the maintenance treatment of adult and adolescent patients (≥ 12 years) with persistent asthma. MF is approved for once or bid maintenance treatment of asthma (in patients previously receiving ICS or bronchodilators). Low… 
Mometasone furoate: an inhaled glucocorticoid for the management of asthma in adults and children
A wide variety of randomized clinical trials have shown the drug to have a clinically beneficial effect on asthma comparable to fluticasone propionate, and to permit the reduction or withdrawal of oral glucocorticoid therapy in patients with asthma.
A review of mometasone furoate/formoterol in the treatment of asthma
The present paper reviews the current knowledge of the novel combination of MF and F for the treatment of asthma and it does not appear from the reviewed literature that MF/F or its individual components are inferior to other equivalent treatments.
Inhaled indacaterol/glycopyrronium/mometasone furoate fixed-dose combination in moderate-to-severe asthma
The recently approved single-inhaler indacaterol/glycopyrronium/mometasone fixed dose combination has demonstrated to significantly reduce exacerbations, improve FEV1, symptoms and quality of life compared to ICS/LABA, including, salmeterol/fluticasone combination.
Emerging corticosteroid agonists for the treatment of asthma
Introduction: Asthma is one of the most frequent chronic diseases worldwide. For decades, asthma has been treated with bronchodilators and inhaled corticosteroids (ICS). However, adverse effects of
Using Lower Doses of Topical Mometasone Furoate in the Treatment of Atopic Dermatitis by Applying Hyaluronic Acid as a Skin Penetration Enhancer
The objective of the present study was to investigate the possibility to add hyaluronic acid (HA) as skin penetration enhancers to mometasone furoate (MF) to enhance its skin absorption, and so
Local delivery of mometasone furoate from an eluting endotracheal tube
Investigation of Appropriate Inhalation Technique for Mometasone Furoate Dry Powder Inhaler.
PIFR but not Tmax PIFR has an effect on lung deposition after inhalation with an MF-DPI, and FPF for the claimed dose was significantly lower than that at 60 L/min, which was dependent on PifR.
Topical Administration of Mometasone Furoate - A Combined Impedance Spectroscopy and In Vitro Drug Diffusion Study
To conclude, cream B appears to be the safer alternative as it does not seem to perturb the skin and imposes less systemic burden without sacrificing clinical efficacy.


Efficacy and safety of mometasone furoate administered once-daily in the evening in patients with persistent asthma dependent on inhaled corticosteroids
Once-daily evening dosing of MF-DPI at doses of 400 and 200 µg restored lung function and improved nocturnal and daytime symptom control in subjects with asthma previously dependent on bid ICS therapy.
Mometasone furoate administered once daily is as effective as twice-daily administration for treatment of mild-to-moderate persistent asthma.
This is the first study to demonstrate that a total daily dose of 400 microg of MF administered by means of a DPI is an effective treatment for patients with mild-to-moderate persistent asthma previously taking only inhaled beta(2)-adrenergic agonists.
Inhaled mometasone furoate: a review of its use in adults and adolescents with persistent asthma.
Inhaled mometasone furoate is well tolerated, with minimal systemic activity and is equally effective when administered as a divided dose or as a single daily dose.
Effects of Mometasone Furoate Given Once Daily in the Evening on Lung Function and Symptom Control in Persistent Asthma
Mometasone furoate dry powder inhaler (MF-DPI) administered once daily in the evening or twice daily in patients with asthma previously maintained on twice-daily regimens of inhaled corticosteroids was as effective in improving pulmonary function, asthma symptoms, and quality of life compared with placebo.
Once-Daily Mometasone Furoate Administered by Dry Powder Inhaler for the Treatment of Children with Persistent Asthma
This 12-week, randomized, double-blinded, parallel-group, multicenter trial is the first study to evaluate the efficacy and safety of mometasone furoate administered by pediatric patients once daily in the morning via a novel dry powder inhaler.
Inhaled mometasone furoate reduces oral prednisone requirements while improving respiratory function and health-related quality of life in patients with severe persistent asthma.
MF inhaled orally as a dry powder is an effective alternative to systemic corticosteroids in patients with severe persistent asthma, and Pulmonary function and quality of life significantly increased for MF-treated patients.
Mometasone furoate: efficacy and safety in moderate asthma compared with beclomethasone dipropionate.
  • R. Nathan, A. Nayak, J. E. Harrison
  • Medicine
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology
  • 2001
Reduction in Oral Corticosteroid Use with Mometasone Furoate Dry Powder Inhaler Improves Health-Related Quality of Life in Patients with Severe Persistent Asthma
Symptomatic improvement and reduction in OCS use with MF DPI were accompanied by significant improvement in HRQL in patients with severe persistent asthma, and improvements were maintained during the 3-month period of the OLE in which HRQL was evaluated.